Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
boston blog main
9
×
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
9
×
detroit blog main
9
×
detroit top stories
indiana blog main
indiana top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
9
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
national
fda
cancer
eli lilly
bristol-myers squibb
cancer immunotherapy
investing
nonalcoholic steatohepatitis
startups
teva pharmaceutical
abbvie
amgen
deals
What
drug
9
×
fda
roundup
approval
bio
new
companies
won
annual
approved
attention
biotech
cancer
class
developed
market
meeting
migraine
nash
news
oral
patients
potential
advantages
agency
ahead
aimmune
allergy
alzheimer’s
ambien
american
amgen
arguments
asco
assessed
attendees
awarded
bar
big
biogen’s
Language
unset
Current search:
drug
×
biotech
×
" detroit blog main "
×
" boston blog main "
×
" clinical trials "
×
" seattle top stories "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines